NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. | ITV National News ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...

NICE decided that two Alzheimer’s drugs are too expensive for their modest benefits and cannot be recommended for NHS use in ...

The National Health Service will not fund two new Alzheimer’s drugs after an official review concluded the treatments cost ...